Gilead Sciences Inc (GILD.OQ)
25 May 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|65||2018||Chairman of the Board|
|55||2016||President, Chief Executive Officer, Director|
|55||2014||Chief Financial Officer, Executive Vice President|
|59||2016||Chief Operating Officer|
|2018||Executive Vice President - Clinical Research, Chief Scientific Officer|
- BRIEF-FDA Approves Expanded Indication For Truvada
- BRIEF-Gilead's Kite Announces New Facilities, Expands Collaboration With National Cancer Institute
- Gilead defeats nonprofit's challenge to AIDS treatment patents
- BRIEF-Gilead Sciences Board Has Declared A Cash Dividend Of $0.57 Per Share Of Common Stock For Q2 Of 2018
- BRIEF-Gilead Sciences Reports Q1 EPS $1.17